查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1654295

破傷風類毒素疫苗市場規模、佔有率、趨勢分析報告：按疫苗、疾病、最終用途、地區、細分預測，2025-2030 年

Tetanus Toxoid Vaccine Market Size, Share & Trends Analysis Report By Vaccine (Diphtheria, Tetanus, And Pertussis (DTaP)), By Disease (Tetanus, Diphtheria), By End Use (Hospital, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 153 Pages | 商品交期: 2-10個工作天內

價格

破傷風類毒素疫苗市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球破傷風類毒素疫苗市場預計到2030年將達到80.9億美元，2025年至2030年期間的複合年成長率為5.67%。

由於人們對免疫計劃的關注度不斷提高以及對疫苗可預防疾病的認知不斷提高，破傷風類毒素疫苗行業正在經歷顯著成長。破傷風是嚴重細菌感染疾病，仍然是全球健康問題，特別是在疫苗接種覆蓋率較低的地區。疫苗接種的普及和醫療保健基礎設施的發展是推動市場擴張的主要因素。

推動市場成長的一個主要因素是能夠提供針對多種疾病的廣譜保護的聯合疫苗。白喉-破傷風-百日咳 (DTaP) 疫苗在小兒科免疫接種計畫中廣泛使用，可確保早期預防這些嚴重感染疾病。同樣，白喉破傷風 (DT) 疫苗對於無法接種百日咳疫苗的人來說是必不可少的，並支持替代疫苗接種選擇。此外，破傷風-白喉-百日咳（Tdap）疫苗在青少年和成年人的加強免疫中發揮重要作用，可以增強長期免疫力，減少疾病傳播。

根據目標疾病對疫苗進行分類，進一步增強了該市場。儘管以破傷風為重點的疫苗仍然是免疫策略的核心，但結合白喉預防將提高整體有效性。加入針對特定病患小組客製化的其他疫苗配方將允許採取更全面的疫苗接種方法，擴大不同人群的接種機會。

分銷管道在疫苗推廣中發揮著至關重要的作用。作為主要的疫苗接種中心，醫院可以方便地提供破傷風類毒素疫苗，特別是在緊急傷口處理情況下。專科診所透過提供常規疫苗接種做出了重大貢獻，特別是針對孕婦和旅行者等高風險族群。此外，社區健康中心和藥局等其他醫療服務提供者也正在擴大其在疫苗接種服務中的作用，提高其市場滲透率。

隨著疫苗配方的不斷進步和政府提高疫苗接種覆蓋率的舉措不斷增多，預計未來幾年市場將實現穩步成長。

破傷風類毒素疫苗市場報告重點

  • 在 2024 年破傷風類毒素疫苗產業中，白喉-破傷風-百日咳 (DTaP) 佔疫苗領域的最大佔有率。這項優勢歸功於 DTaP 在常規免疫計劃中的廣泛應用，特別是在兒童和加強疫苗接種計劃中，可為多種細菌感染提供全面的保護。
  • 根據疾病，破傷風將繼續成為 2024 年市場成長的主要貢獻者。破傷風相關併發症的發生率很高，尤其是在未接種疫苗的人群以及新生兒和創傷患者等高風險人群中，這增加了對有效疫苗接種策略的需求，使得破傷風類毒素疫苗接種變得越來越重要。
  • 在終端使用領域，醫院將在 2024 年佔據市場主導地位。醫院在疫苗接種計劃、緊急預防和破傷風暴露後管理中發揮關鍵作用，確保及時接種疫苗，特別是在治療損傷和傷口方面。訓練有素的醫療專業人員的存在進一步提高了醫院疫苗接種的效率。
  • 由於先進的醫療基礎設施、完善的疫苗接種計劃以及人們對疫苗可預防疾病的認知不斷提高，北美在 2024 年引領了市場。政府推出的優惠政策和舉措，推動常規和補貼免疫，進一步增強了該地區的市場優勢。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 破傷風類毒素疫苗市場變因、趨勢與範圍

  • 母市場展望
  • 補貼市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 破傷風類毒素疫苗分析工具
    • 波特的分析
    • PESTEL 分析

第 4 章破傷風類毒素疫苗市場：疫苗估計與趨勢分析

  • 破傷風類毒素疫苗市場：疫苗區隔儀表板
  • 破傷風類毒素疫苗市場：疫苗變異分析，2024 年及 2030 年
  • 白喉、破傷風和百日咳 (DTaP)
  • 白喉和破傷風 (DT)
  • 破傷風-白喉-百日咳 (Tdap)

第 5 章破傷風類毒素疫苗市場：疾病評估與趨勢分析

  • 破傷風類毒素疫苗市場：疾病區隔儀表板
  • 破傷風類毒素疫苗市場：疾病變異分析，2024 年及 2030 年
  • 破傷風
  • 白喉
  • 其他

6. 破傷風類毒素疫苗市場：最終用途估計與趨勢分析

  • 破傷風類毒素疫苗市場：最終用途細分儀表板
  • 破傷風類毒素疫苗市場：2024 年和 2030 年最終用途變化分析
  • 醫院
  • 專科門診
  • 其他

第 7 章破傷風類毒素疫苗市場：區域估計與趨勢分析

  • 2024 年及 2030 年破傷風類毒素疫苗各地區市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 南非

第8章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司熱圖分析
  • 公司簡介
    • Pfizer, Inc.
    • GSK plc.
    • Sanofi
    • Merck &Co., Inc.
    • Grifols, SA
    • Emergent BioSolutions Inc.
    • Virbac
    • Zoetis Services LLC
    • Ceva.
    • Abbott
Product Code: GVR-4-68040-502-4

Tetanus Toxoid Vaccine Market Growth & Trends:

The global tetanus toxoid vaccine market size is anticipated to reach USD 8.09 billion by 2030 and is expected to expand at a CAGR of 5.67% from 2025 to 2030, according to a new report by Grand View Research, Inc. The tetanus toxoid vaccine industry is witnessing significant growth due to the increasing focus on immunization programs and rising awareness about vaccine-preventable diseases. Tetanus, a severe bacterial infection affecting the nervous system, remains a global health concern, particularly in regions with low vaccination coverage. The expanding adoption of vaccination drives and improved healthcare infrastructure are key factors propelling market expansion.

A major contributor to market growth is the availability of combination vaccines, which provide broader protection against multiple diseases. The Diphtheria, Tetanus, and Pertussis (DTaP) vaccine is widely administered in pediatric immunization schedules, ensuring early protection against these serious infections. Similarly, the Diphtheria and Tetanus (DT) vaccine is essential for individuals who cannot receive the pertussis component, supporting alternative immunization options. Additionally, the Tetanus, Diphtheria, and Pertussis (Tdap) vaccine plays a crucial role in booster doses for adolescents and adults, reinforcing long-term immunity and reducing disease transmission.

The market is further strengthened by the classification of vaccines based on target diseases. While Tetanus-focused vaccines remain central to immunization strategies, the integration of Diphtheria protection enhances overall effectiveness. The inclusion of other vaccine formulations tailored for specific patient groups contributes to a more comprehensive immunization approach, expanding accessibility across diverse populations.

Distribution channels play a pivotal role in ensuring widespread vaccine availability. Hospitals serve as primary immunization centers, offering immediate access to tetanus toxoid vaccines, especially in emergency wound management cases. Specialty clinics contribute significantly by providing routine vaccinations, particularly for high-risk groups such as pregnant women and travelers. Additionally, other healthcare providers, including community health centers and pharmacies, are expanding their role in vaccination services, enhancing market penetration.

With continuous advancements in vaccine formulations and increasing governmental efforts to improve immunization rates, the market is poised for steady growth in the coming years.

Tetanus Toxoid Vaccine Market Report Highlights:

  • The vaccine segment of Diphtheria, Tetanus, and Pertussis (DTaP) held the largest share of the tetanus toxoid vaccine industry in 2024. This dominance can be attributed to the widespread adoption of DTaP in routine immunization programs, offering comprehensive protection against multiple bacterial infections, particularly in pediatric and booster vaccination schedules.
  • In the disease segment, tetanus remained the dominant contributor to market growth in 2024. The high incidence of tetanus-related complications, particularly in unvaccinated populations and high-risk groups such as newborns and trauma patients, has driven demand for effective vaccination strategies, reinforcing the importance of tetanus toxoid immunization.
  • In end-use segment, hospitals dominated the market in 2024. Hospitals play a crucial role in vaccination programs, emergency prophylaxis, and post-exposure tetanus management, ensuring timely administration of vaccines, especially in cases of injuries and wound care. The availability of trained healthcare professionals further supports the efficiency of hospital-based immunization.
  • North America led the market in 2024, driven by advanced healthcare infrastructure, well-established immunization programs, and increasing awareness about vaccine-preventable diseases. Favorable government policies and initiatives promoting routine and booster vaccinations have further contributed to regional market dominance.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Tetanus Toxoid Vaccine Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing government immunization programs
      • 3.3.1.2. Rising awareness & preventive healthcare
      • 3.3.1.3. Increasing birth rates & pediatric vaccination
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Vaccine shortages & supply chain issues
      • 3.3.2.2. Low awareness in developing regions
  • 3.4. Tetanus Toxoid Vaccine Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Tetanus Toxoid Vaccine Market: By Vaccine Estimates & Trend Analysis

  • 4.1. Tetanus Toxoid Vaccine Market: Vaccine Segment Dashboard
  • 4.2. Tetanus Toxoid Vaccine Market: By Vaccine Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Diphtheria, Tetanus, and Pertussis (DTaP)
    • 4.3.1. Diphtheria, Tetanus, and Pertussis (DTaP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Diphtheria and Tetanus (DT)
    • 4.4.1. Diphtheria and Tetanus (DT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tetanus, Diphtheria and Pertussis (Tdap)
    • 4.5.1. Tetanus, Diphtheria and Pertussis (Tdap) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Tetanus Toxoid Vaccine Market: Disease Estimates & Trend Analysis

  • 5.1. Tetanus Toxoid Vaccine Market: Disease Segment Dashboard
  • 5.2. Tetanus Toxoid Vaccine Market: By Disease Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Tetanus
    • 5.3.1. Tetanus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Diphtheria
    • 5.4.1. Diphtheria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Tetanus Toxoid Vaccine Market: End Use Estimates & Trend Analysis

  • 6.1. Tetanus Toxoid Vaccine Market: End Use Segment Dashboard
  • 6.2. Tetanus Toxoid Vaccine Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Specialty Clinics
    • 6.4.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Tetanus Toxoid Vaccine Market: Regional Estimates & Trend Analysis

  • 7.1. Tetanus Toxoid Vaccine Market Share, By Region, 2024 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Kuwait
      • 7.6.4.1. Kuwait Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa Tetanus Toxoid Vaccine Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. GSK plc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Sanofi
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Merck & Co., Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Grifols, S.A.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Emergent BioSolutions Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Virbac
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Zoetis Services LLC
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Ceva.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Abbott
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables:

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 4 Global Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 5 Global Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 8 North America Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 9 North America Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 11 U.S. Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 12 U.S. Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Canada Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 14 Canada Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 15 Canada Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Mexico Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 17 Mexico Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 18 Mexico Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 21 Europe Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 22 Europe Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 24 Germany Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 25 Germany Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 U.K. Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 27 U.K. Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 28 U.K. Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 France Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 30 France Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 31 France Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Italy Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 33 Italy Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 34 Italy Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Spain Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 36 Spain Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 37 Spain Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Denmark Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 39 Denmark Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 40 Denmark Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Sweden Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 42 Sweden Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 43 Sweden Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Norway Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 45 Norway Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 46 Norway Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 China Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 52 China Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 53 China Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Japan Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 55 Japan Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 56 Japan Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 India Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 58 India Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 59 India Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 South Korea Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 61 South Korea Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 62 South Korea Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 Australia Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 64 Australia Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 65 Australia Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Thailand Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 67 Thailand Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 68 Thailand Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 71 Latin America Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 72 Latin America Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Brazil Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 74 Brazil Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 75 Brazil Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 77 Argentina Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 78 Argentina Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Tetanus Toxoid Vaccine Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Africa Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 84 South Africa Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 85 South Africa Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 90 UAE Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 91 UAE Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Tetanus Toxoid Vaccine Market, by Vaccine, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Tetanus Toxoid Vaccine Market, by Disease, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Tetanus Toxoid Vaccine Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Tetanus toxoid vaccine market segmentation
  • Fig. 8 Market snapshot, 2024
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Market challenge relevance analysis (current & future impact)
  • Fig. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Tetanus toxoid vaccine market: Vaccine movement analysis
  • Fig. 16 Tetanus toxoid vaccine market: Vaccine outlook and key takeaways
  • Fig. 17 Diphtheria, tetanus, and pertussis (DTaP) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 18 Diphtheria and tetanus (DT) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 19 Tetanus, diphtheria and pertussis (Tdap) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 20 Tetanus, Diphtheria and Pertussis (Tdap) tetanus toxoid vaccine market estimates and forecasts, 2018 - 2030
  • Fig. 21 Tetanus toxoid vaccine market: Disease movement analysis
  • Fig. 22 Tetanus toxoid vaccine market: Disease outlook and key takeaways
  • Fig. 23 Tetanus market estimates and forecasts, 2018 - 2030
  • Fig. 24 Diphtheria market estimates and forecasts, 2018 - 2030
  • Fig. 25 Others market estimates and forecasts, 2018 - 2030
  • Fig. 26 Tetanus toxoid vaccine market: End use movement analysis
  • Fig. 27 Tetanus toxoid vaccine market: End use outlook and key takeaways
  • Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 29 Specialty clinics market estimates and forecasts, 2018 - 2030
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030
  • Fig. 31 Regional Marketplace: Key Takeaways
  • Fig. 32 Regional Outlook, 2024 & 2030
  • Fig. 33 Global tetanus toxoid vaccine market, Region Movement Analysis
  • Fig. 34 North America tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 36 Canada tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 40 U.K. tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 41 France tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 49 China tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 50 India tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 60 UAE tetanus toxoid vaccine market, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait tetanus toxoid vaccine market, 2018 - 2030 (USD Million)